Accelerate clinical trial cycle times by sele...

Minimizing Luck in Study Feasibility

This informative whitepaper introduces you to best practices in study feasibility, which laid the groundwork for our new predictive analytic that is launching soon, Citeline Study Feasibility.  Our industry-leading technology will deliver advanced insight to improve your clinical trial decisions, fast-track enrollment and optimize cycle times – all with less effort.

Citeline Connect

Patient Perspectives on Clinical Trial Participation Report

Informa Pharma Intelligence partnered with Rare Patient Voice to measure the pulse of the public in relation to clinical trial participation post-COVID-19

Minimizing Luck in Study Feasibility Part 2

Study feasibility is a fundamental contributor to the overall success of a clinical development program. However, selecting the right countries, sites and investigators and starting up as quickly as possible remains a challenge, leading to greatly variable performance and inaccurate predictions for important trial milestones.

Citeline

Q2 2021 Clinical Trials and the COVID-19 Vaccine Pulse Report

The goal of our second Clinical Trials & the COVID-19 Vaccine Pulse Report is to uncover who is still hesitant to take a vaccine, and what public health experts from pharma to the U.S. government can do to turn the tide.

Citeline, Trialtrove: 医療用医薬品の臨床試験情報データベース

2020 Completed Trials A Bumpy Road for Industry Sponsored Clinical Studies

Over the past five years, our analysis of completed trials consistently observed growth trends.

Trial Results Summaries

Trial results transparency starts here

Trial Results Summaries provides an unbiased and non-promotional portal for sponsors to share trial results summaries, also known as plain language summaries (PLS), with participants and the public.

AstraZeneca takes an innovative approach to trial results summaries

What Are Trial Results Summaries and Why Are They Necessary?

Citeline

Clinical Trial Webinar Series

Learn about the latest trends affecting biopharma R&D including, study diversity & transparency, predictive feasibility and more...